Defying low expectations set almost a year ago by an interim peek at phase III data, Sophiris Bio Inc.'s PRX302 (topsalysin) rose to meet its primary endpoint of statistically significant improvement of benign prostatic hyperplasia (BPH) symptoms over 12 months in final data released Tuesday.